Adage Capital Partners Gp, L.L.C. Ventyx Biosciences, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.9 - $10.13 $1.26 Million - $6.74 Million	665,050 Added 110.84%	1,265,050 $6.96 Million
Q4 2023 Feb 14, 2024	SELL	$2.08 - $31.18 $806,977 - $12.1 Million	-387,970 Reduced 39.27%	600,000 $1.48 Million
Q3 2023 Nov 14, 2023	BUY	$29.8 - $40.3 $26.7 Million - $36.1 Million	895,000 Added 962.68%	987,970 $34.3 Million
Q2 2023 Aug 14, 2023	SELL	$28.53 - $39.55 $11.8 Million - $16.3 Million	-411,945 Reduced 81.59%	92,970 $3.05 Million
Q1 2023 May 15, 2023	SELL	$29.51 - $46.65 $27 Million - $42.7 Million	-916,330 Reduced 64.47%	504,915 $16.9 Million
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $24.7 Million - $37.2 Million	1,021,245 Added 255.31%	1,421,245 $46.6 Million
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $5.06 Million - $15.5 Million	400,000 New	400,000 $14 Million

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $116M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.